Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

NCT00629473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: NPI-0052 on Days 1, 8, 15 every 28 days
DRUG: NPI-0052 on Days 1, 4, 8, 11 every 21 days
DRUG: Dexamethasone

Sponsor

Celgene